参考资料 [1]Chen J,et al.Measurable residual disease (MRD)-testing in haematological and solid cancers[J]. Leukemia, 2024, 38(6): 1202-1212.https://www.nature.com/articles/s41375-024-02252-4 [2]Shaw JA,et al.Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value...
参考资料 [1]Chen J,et al.Measurable residual disease (MRD)-testing in haematological and solid cancers[J]. Leukemia, 2024, 38(6): 1202-1212. https://www.nature.com/articles/s41375-024-02252-4 [2]Shaw JA,et al.Serial Postoperative C...
The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.
Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for the assessment of MRD and risk of recurrence in real time.1A ctDNA assay optimized for MRD detection must be able to detect ctDNA at the lowest level of residual disease burden, the point at which patients are most likel...
1. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. 2. Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers. Speaker: Everett Moding, ...
1. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. 2. Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers. Speaker: Everett Moding, ...
$ 2,750.00 USD Katie Maloney Partner Rebecca Burnham Senior Product Manager DeciBio conducted 10 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care. Key themes discussed...
505P Early experience in using tissue-free minimal residual disease (MRD) testing in early-stage solid tumor patients from Asia and the Middle Eastdoi:10.1016/j.annonc.2024.10.530S. DawoodV. LavingiaC-M. TsaiS. HsingS.S. JainAnnals of Oncology...
2024年4月18日,中国医学科学院血液病医院(中国医学科学院血液学研究所)陈俊仁团队在《Leukemia》发表观点性文章“Measurable residual disease (MRD)-testing in haematological and solid cancers”。该研究基于大量文献数据,探讨是否有令人信服的数据证明...
1. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. 2. Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers. Speaker: Everett Moding, ...